TrialBMC ophthalmology2024

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.

David Wirta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.